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nhibition of immune protection
a  b  s  t  r  a  c  t
Aeromonas  salmonicida  subsp.  salmonicida  is  the  etiologic  agent  of  furunculosis,  a frequent  and  signiﬁcant
disease  of ﬁsheries  worldwide.  The  disease  is  largely  controlled  by commercial  oil adjuvanted  vaccines
containing  bacterins.  However,  the  mechanisms  leading  to a protective  immune  response  remain  poorly
understood.  The  type-three  secretion  system  (T3SS)  plays  a  central  role  in  virulence  of  A. salmonicida
subsp.  salmonicida  and  thus  may  have  an  inﬂuence  on  the  immune  response  of  the  host.  The  aim  of  this
study  was  to evaluate  the role  of  the  T3SS  antigens  in  mounting  a  protective  immune  response  against
furunculosis.
Rainbow  trout  were  intraperitoneally  vaccinated  in  two  independent  experiments  with  bacterins  pre-
pared from  a  wild-type  A.  salmonicida  strain  and  an  isogenic  strain  carrying  a  deletion  in the  T3SS (ascV).
Fish were  challenged  with  the  wt  strain  eight  weeks  after  vaccination.  In both  trials,  the survival  rate  of
trout  vaccinated  with  the  ascV  strain  was  signiﬁcantly  higher  (23–28%)  in  comparison  to the  group
vaccinated  with  the  wt  strain.  High-throughput  proteomics  analysis  of  whole  bacteria  showed  the  ascV
deletion  in  the  mutant  strain  resulted  in  lower  expression  of  all the components  of the T3SS,  several  of
which  have  a  potential  immunosuppressive  activity.  In  a third  experiment,  ﬁsh  were  vaccinated  with
recombinant  AcrV  (homologous  to  the  protective  antigen  LcrV  of  Yersinia)  or S-layer  protein  VapA  (con-
trol). AcrV  vaccinated  ﬁsh  were  not  protected  against  a  challenge  while  ﬁsh  vaccinated  with  VapA  were
partially protected.
The  presence  of  T3SS  proteins  in  the  vaccine  preparations  decreased  the  level  of protection  against  A.
salmonicida  infection  and  that  AcrV  was  not  a  protective  antigen.  These  results  challenge  the  hypothesis
that  mounting  speciﬁc  antibodies  against  T3SS  proteins  should  bring  better  protection  to  ﬁsh  and  demon-
strate  that  further  investigations  are  needed  to  better  understand  the  mechanisms  underlying  effective
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1. Introduction
The Gram-negative bacterium Aeromonas salmonicida subsp.
salmonicida (hereafter referred to as A. salmonicida) is the
etiologic agent of furunculosis. This disease, ﬁrst described by
Lehmann and Neumann in 1896 [1], can affect all salmonid species
and is a frequent and signiﬁcant pathogen of ﬁsheries worldwide.
Furunculosis results in marked-economic losses and drives the
intensive use of antibiotics [2]. It has been more than 70 years
since the ﬁrst protective vaccination trials against furunculosis
were reported [3]. For the past 20 years, the disease has been largely
controlled by the use of protective commercialized oil-adjuvanted
vaccines containing A. salmonicida bacterins [4]. Numerous trials
have been performed in order to optimize vaccination and to eluci-
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ave been contradictory and certain antigens capable of producing
gglutinating antibodies against A. salmonicida were not protective
5–7]. Furthermore, several authors have suggested that the pro-
ection observed was, in part non-speciﬁc [8]. In contrast, passive
mmunization of ﬁsh with immune sera directed against whole A.
almonicida antigens have shown that humoral factors were able to
rotect ﬁsh [9,10] and others have found that the level of protection
orrelated with the level of speciﬁc antibodies in the serum [11,12].
 certain degree of protection with speciﬁc antigens of A. salmoni-
ida (such as VapA) [13] has been obtained but the immunological
echanisms leading to a protective immune response remains
oorly understood while the effect of AcrV in protective immunity
as not been studied yet.
Ten years ago, our laboratory published the ﬁrst descriptions
f the type-three secretion system (T3SS) in the Aeromonas genus
nd demonstrated its role as a virulence factor of A. salmonicida
14–16]. The T3SS is, in essence, a nanosyringe composed of inner-
nd outer membrane rings, a needle with a tip and the translocon
hat injects virulent effector proteins directly into the cytoplasm of
he host cell. Despite the prominent role of the T3SS in the patho-
enesis of A. salmonicida [16–18], knockout mutants of individual
3SS effector genes only partially reduce virulence or delay the
nset of the disease after challenge [17]. The aim of the present
ork was to characterize the protective effect of the T3SS on immu-
ized ﬁsh by vaccinating rainbow trout with a formalin-killed wt
. salmonicida strain and an isogenic ascV mutant, characterized
s T3SS-deﬁcient.
. Materials and methods
.1. Bacterial strains and growth conditions
Bacterins were prepared from the following A. salmonicida
ubsp. salmonicida strains: wt strain JF5054 (isolated from a trout
fter experimental infection with strain JF2267 [16]), an ascV
utant (JF2747) and strain JF3239 (ascV/ascV+) in which the
scV deletion is complemented in trans [18,19]. The wt strain
F2267 was isolated from an arctic char (Savelinus alpinus) and is
irulent with intraperitoneal inoculation of 500 colony-forming
nits (CFU) per ﬁsh, sufﬁcient to induce 70–80% of mortality in
hallenge assays. The isogenic ascV mutant strain was shown
o be non-virulent since 105 CFU per ﬁsh induced no mortal-
ty [18]. Each strain was grown in TSB medium or onto TSA
lates at 18 ◦C with the appropriate antibiotics at the follow-
ng ﬁnal concentrations: kanamycin (40 g/mL) and ampicillin
100 g/mL).
.2. Fish
All animals used in this study have been treated according to
he Swiss regulations for animal welfare.
The initial bacterin vaccination experiment utilized rainbow
rout (Onchorhynchus mykiss)  of 11 ± 2 cm length and 17 ± 1.5 g
eight. Ten ﬁsh were transferred to each of six 30 L glass aquaria
quipped with a tap water ﬂow through system and aeration.
emperature was maintained at 17.6 ± 0.4 ◦C. Fish were fed a com-
ercial trout diet at a rate of 1.5% of the body weight; the diet rate
as adjusted weekly.
In the second experiment, initial weight of the ﬁsh was  23 ± 1.5 g
nd length was 12 ± 1 cm.  Ten ﬁsh were placed in each of eight 30 L
lass tanks. Temperature was maintained at 15 ± 0.8 ◦C. Fish were
ed commercial diet at a rate of 2% of the body weight; the diet rate
as adjusted weekly.
Vaccination with puriﬁed proteins was carried out with trout
f mean weight 1.5 g. Eighty ﬁsh were placed in each of four 130 L1 (2013) 5256– 5261 5257
glass tanks. Temperature was maintained at 16 ± 1 ◦C. Fish were fed
commercial diet at a rate of 2.5% of the body weight; the diet rate
was  adjusted weekly.
2.3. Vaccine preparation
For the preparation of bacterins, 109 bacteria of each strain were
inoculated in 50 mL  of TSB medium and cultivated overnight at
18 ◦C with aeration (160 rpm). Bacterial growth was  stopped dur-
ing exponential growth (optical density at 600 nm (OD600 = ∼1.5).
Bacterial suspensions containing 2 × 109 CFU were harvested by
centrifugation and inactivated with 1.5% formaldehyde for 2 h at
20 ◦C under gentle shaking; inactivation of the bacteria was con-
ﬁrmed by cultivation on TSA plates. Suspensions were washed once
with PBS pH 7.4 and then resuspended in PBS to obtain a bacterial
concentration of 4 × 108 bacterins/mL. This suspension was  mixed
with 1:1 volume of aluminium hydroxide gel (Sigma) before vac-
cination and ﬁsh were inoculated with 107 bacterins per 50 L of
vaccine solution.
Recombinant AcrV (rAcrV) was  expressed in E. coli following
cloning of the wt  acrV gene in the pETHis-1 vector [20]. Puriﬁcation
of the protein was  carried out by Ni2+ chelation chromatography
[21].
VapA was prepared directly from the wt A. salmonicida strain
JF2267. Brieﬂy, bacteria were cultivated in TSB medium until
an OD600 of 0.2 was  reached. Cells were harvested by centrifu-
gation, washed with 0.85% NaCl and, then suspended in 10 mL
0.1 M glycin. A 500 L volume of 1 M HCl pH 2.2 was  added
to the suspension before gentle shaking (180 rpm) on ice for
30 min. Cells were removed by centrifugation and the super-
natant mixed with 500 L of Tris Base pH 7.0. The suspension
was  again shaken on ice for 30 min, and then centrifugated for
1 h at 18,000 rpm and 4 ◦C. The supernatant was then desalted
on an Amicon column (Millipore) with a molecular weight cut-off
of 30 kDa. The presence of concentrated VapA was conﬁrmed by
SDS-PAGE, which showed the presence of the protein with high
purity.
Total amounts of AcrV and VapA proteins were measured with
a Bradford assay [22]. Concentrations were adjusted with PBS and
mixed in a 1:1 volume with an oil adjuvant (PharmaQ, Norway)
to reach a ﬁnal concentration of 3 g protein per 50 L of vaccine
solution.
2.4. Vaccination
Prior to vaccination, ﬁsh were anesthetized using 50 mg/L
buffered 3-aminobenzoic acid ethyl ester (MS-222, Argent Chem-
ical Laboratories) and then individually injected intraperitoneally
(i.p.) with 50 L of vaccine or PBS (as a control). Immediately after
injection, ﬁsh were placed back in the tanks. In the experiment
with puriﬁed A. salmonicida rAcrV and VapA proteins, ﬁsh received
a second vaccination dose 5 weeks after the ﬁrst injection.
2.5. Challenge
Fish were challenged with the wt  strain of A. salmonicida JF5054.
In both experiments using bacterins, the challenge was performed
8 weeks after vaccination. Fish were anesthetized using 50 mg/L
buffered 3-aminobenzoic acid ethyl ester and then i.p. injected with
5 × 102 CFU in 50 L of PBS. Following vaccination with AcrV and
VapA, trout were challenged by i.p. injection with 2 × 102 CFU in
50 L of PBS 10 weeks after the ﬁrst vaccination (5 weeks after the
boost).



































Fig. 1. Survival of ﬁsh vaccinated with bacterins and subsequently challenged with
A.  salmonicida. Panels A and B present the results of two  independent vaccination
experiments with bacterins (107/ﬁsh) prepared from wild-type (virulent) and iso-
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.6. Mass spectrometry
To analyze the impact of the ascV deletion on the T3SS of A.
almonicida, 50 mL  of TSB medium were inoculated with 109 wt
r ascV strain and cultivated at 18 ◦C with aeration (160 rpm) in
resence of protease inhibitor (Complete, Roche Diagnostics). Cells
ere harvested during the exponential growth (OD600 = 1.5). Cells
ere washed in PBS before being mixed in a 1:1 volume with SDS
oading buffer and heated at 100 ◦C for 5 min. Proteins were sepa-
ated in non-adjacent wells (to avoid well to well contamination)
n 15% acrylamide SDS-PAGE gels and stained with Coomassie. The
el (one lane for each condition) was completely sliced from the
tacking gel to the buffer front in 20–25 bands for protein in-gel
igestion and MS  analysis as described elsewhere [23,24].
.7. LC–MS/MS data interpretation
LC–MS/MS data interpretation was conducted using the current
niProtKB database release (2012 06) of all known A. salmoni-
ida protein sequences. The peptide-matching score summation
PMSS) method of relative protein quantiﬁcation was  used. This is a
abel-free technique that assumes ideal scoring for proteins as the
ummative of the identiﬁcation scores of their constituent peptides
reed upon digestion. A higher score represents a more abundant
rotein [25]. For this, the EasyProt search algorithm [26] was  used
s previously described [27].
.8. Bioinformatics and statistics
The tridimensional structures of A. salmonicida AcrV was
odelled using the crystal structures of Yersinia LcrV (PDB
D:1R6F) as a template for the automated mode of SWISS-MODEL
http://swissmodel.expasy.org) and the assembly of LcrV subunits
o represent the T3SS pentameric tip complex of Yersinia was  made
ith SwissPdb Viewer [28] and reproduced as described previously
29].
The Chi-square (2) test with Yates’ correction was  used to
ssess if the difference in the survival rate between the groups
accinated with the wt or ascV mutant strain was  statistically
igniﬁcant.
. Results and discussionIn a ﬁst assay, ﬁsh were vaccinated with the wt strain, the ascV
utant or with PBS only (control group). Eight weeks later, all ﬁsh
ere challenged with 5 × 102 CFU/animal of wt A. salmonicida. Fish
ig. 2. Relative amounts of A. salmonicida T3SS proteins in wt  and ascV mutant pellet
t  cell pellets (grey bars) versus the ascV mutant cell pellets (white columns) used to
 = T3SS chaperone; CR = C-ring; E = effector; IR = inner membrane ring; N = needle; OR = o
lyceraldehyde-3-phosphate dehydrogenase (GAPDH) are illustrated as reference values.only.
were monitored for 9 days post-infection (dpi) by which time the
survival rate in the control group had plateaued at 32% (Fig. 1A).
Vaccination with the inactivated wt  strain brought no signiﬁcant
protection with 37% survival measured at 8 dpi (versus 32% for the
control group) (Fig. 1A). In contrast, the group vaccinated with the
ascV mutant showed signiﬁcant protection with a survival rate of
65% by day 6 post-inoculation (Fig. 1A).
s used to prepare bacterins. The histogram shows the amount of T3SS proteins in
 prepare the bacterins. Structural roles of the T3SS proteins are given as follows:
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In a second, independent experiment using the same parame-
ers, onset of mortality was on day 4 dpi in all 4 groups. By day
1 dpi, the survival rate in the control group was  10% whereas sur-
ival of ﬁsh vaccinated with the wt strain was 42% (Fig. 1B). The level
f protection was highest in the group vaccinated with the deletion
utant ascV at 65% survival. A fourth vaccination group that was
accinated with a bacterin prepared from the ascV mutant strain
omplemented in trans with the wt ascV gene [19] (ascV/ascV+) had
 survival rate of 50% (data not shown). In both trials, vaccination
ith the ascV mutant resulted in an improved survival rate in
omparison to the group vaccinated with the wt  strain (Fig. 1). A
hi-square test with Yates’ correction (wt versus ascV vaccina-
ion) was performed with the results from both experiments This
nalysis revealed the statistic signiﬁcance of the difference in the
urvival rate between the groups vaccinated with the wt  or ascV
utant strain (2 = 4.559 with 1 degrees of freedom, two-tailed P
alue = 0.0328). The results of these experiments were unexpected
ig. 3. Structural representation of Yersinia LcrV and A. salmonicida AcrV and the predicte
son  of Yersinia LcrV and A. salmonicida AcrV. Amino acid residues in red and dark blue co
8–47  and 271–300 in LcrV) [41,43].
)  The predicted pentameric AcrV tip structure of A. salmonicida T3SS. Amino acid residues
lation in LcrV [41,43]. Amino acids in dark green represent the region corresponding to 
ellow  show the BA5 plague protective epitope of LcrV [50].1 (2013) 5256– 5261 5259
and challenged the hypothesis that mounting speciﬁc antibodies
against proteins of the T3SS yields in better protection.
In order to study the antigenic differences between the wt
and the ascV mutant, we performed a high-throughput semi-
quantitative proteomic analysis of the major proteins present
in cell-pellets of the wt and ascV mutant strains, which were
used to prepare the bacterins. The ascV deletion mutant had sig-
niﬁcantly reduced quantities of almost all components of the
T3SS in comparison to the wt  strain (Fig. 2 and Supplementary
Table 1). Furthermore, the difference in amount of T3SS pro-
teins was  the principle difference between the two strains. Taken
together, the results suggested that one or more components of
the T3SS present in the wt strain may  partially inhibit the estab-
lishment of an efﬁcient immune response.Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.
08.057.
d pentameric AcrV tip complex of the T3SS in A. salmonicida. (A) Structural compar-
rrespond to conserved regions associated to immunomodulation in LcrV (residues
 in red and dark blue correspond respectively to regions associated to immunomod-
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There are published observations that support this hypothe-
is. For example, AcrV and AopB homologues in Yersinia (LcrV
nd YopB) mediated immunosuppression when they are exposed
o host immune cells [30,31]. Furthermore, homologues in other
athogenic bacteria of the effectors AopH [32], AexT [33], AopP [34],
opO [35] and AopN [36] and the regulator ExsB [37] are immuno-
uppressive when they are translocated or expressed directly in
he host cells (short distance effect). These effectors are produced
t strongly reduced amounts in the ascV mutant strain (Fig. 2).
owever, it is not known if these T3SS proteins interact, like
crV, with receptors of the innate immune system to play an
mmunomodulatory role when they are secreted into the extra-
ellular environment of host cells (putative long distance effect)
30]. In this case, the lower amount of effectors/translocators in
ascV bacterins might also explain why the vaccination with the
nactivated ascV mutant brought a better protection than the
nactivated wt strain.
The best described example of T3SS playing a role in disrupting
he host defence is likely LcrV, which forms the tip of the T3SS
eedle and translocon subunit of Yersinia. This protein inhibits
ost inﬂammatory responses [38,39], ampliﬁed the release of IL-
0 from host cells [30,40,41] and induces immunosuppression by
romoting the differentiation of tolerogenic dendritic cells via the
nteraction with TLR2/TLR6 and CD14 receptors [42].
Two regions of LcrV at least were shown to be associated with
he induction of the IL-10 immunomodulatory responses (Fig. 3A)
41,43]. A. salmonicida AcrV shows a high conservation with these
ragments of LcrV (66% and 93% of similarity) and these are exposed
n the outside of the predicted pentameric tip complex (Fig. 3B).
e predicted that these conserved regions could play the same
mmunomodulatory function in AcrV. This assumption is supported
y the observation that IL-10 levels were signiﬁcantly down-
egulated in mice infected with a acrV mutant of Aeromonas
ydrophila [44]. Thus, it may  be possible that immunosuppressive
crV present in our w.t. bacterin preparations (Fig. 2) interfered
ith vaccination against furunculosis.
In vitro, speciﬁc polyclonal antibodies against AcrV protect ﬁsh
ells from the cytotoxicity induced by A. salmonicida [20] however,
he protective effect of AcrV in ﬁsh vaccination is not known. To
larify this point, we immunized ﬁsh with either puriﬁed recom-
inant A. salmonicida AcrV (rAcrV) or puriﬁed VapA (control for a
rotective effect [13]) (Fig. 4).
ig. 4. Survival of ﬁsh following vaccination with puriﬁed proteins and subsequent
hallenge with A. salmonicida
urvival rates of ﬁsh were vaccinated with PBS (control), oil adjuvant only, rAcrV
3  g/ﬁsh) + adjuvant or VapA suspension (3 g/ﬁsh) + adjuvant are given. Fish were
iven booster doses 5 weeks after vaccination and challenged (2 × 102 CFU/animal)
0 weeks after vaccination.
[
[1 (2013) 5256– 5261
While vaccination with VapA offered some degree of protection,
vaccination with rAcrV showed no protection against challenge
with the wt  strain (Fig. 4). Similar observations have been made
with the tip complex protein Bsp22 of Bordetella bronchiseptica [45]
and BipD of Burkholderia pseudomallei for which vaccination with
the recombinant protein brought no protection [46] while the vac-
cination with a live bipD was partially protective [47]. Of note,
the protective antigenic region of LcrV is conformational and found
between amino acids 135 and 275 [48] (Fig. 3A) which only presents
a weak similarity with AcrV. This domain corresponds to the entry
of the T3SS pentameric tip complex (Fig. 3B).
4. Conclusions
Vaccination of rainbow trout with bacterins prepared from a
wt,  virulent strain and an isogenic T3SS mutant of A. salmonicida
indicated the presence of T3SS proteins in the vaccine prepa-
ration decreased the level of protection against A. salmonicida
infection. These results challenge the hypothesis that antibodies
against the T3SS will provide better protection and demonstrate
that further investigations are needed to better our understanding
of immune responses against A. salmonicida. To this end, we rec-
ommend that future publications involving A. salmonicida bacterin
vaccines describe how the vaccines are prepared and mention if the
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